Intellia Therapeutics is a cash-burning gene editing company with two high-concentration pipeline programs — lonvo-z for HAE and nex-z for ATTR amyloidosis — where short interest of 44% reflects deep skepticism, but a perfect 4-quarter earnings beat streak and 78% analyst upside indicate institutional believers see a path to significant value creation.
Thesis pillars
- Dual Pipeline Concentration Risk↓Deteriorating
- Extreme Short Interest Skepticism↓Deteriorating
- Cash Burn Below Quality Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.85; Below-average business quality.
Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis, both designed as one-time in vivo treatments. The planned U.S. commercial launch for lonvo-z targets the first... Read more
Sell if holding. Engine safety override at $10.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.85; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.7/10, high confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Intellia Therapeutics, Inc.
About Intellia Therapeutics, Inc.
Intellia Therapeutics is advancing two in vivo CRISPR therapies in Phase 3: lonvo-z for hereditary angioedema (HAE), with topline data from the 80-patient HAELO study expected mid-2026 and BLA submission planned for the second half of 2026; and nex-z for ATTR amyloidosis, with the MAGNITUDE Phase 3 trial (more than 650 enrolled patients for ATTR-CM) on FDA clinical hold since October 29, 2025, while the MAGNITUDE-2 study for ATTRv-PN had its hold lifted in January 2026 with enrollment expected to complete in the second half of 2026.
Intellia generates pre-commercial revenue primarily through collaboration arrangements. Nex-z is co-developed with Regeneron Pharmaceuticals, which shares approximately 25% of worldwide development costs and commercial profits under the ATTR co-development and co-promotion agreement; Intellia serves as the clinical and commercial lead. Under the 2016 Regeneron Agreement, Intellia is eligible for up to $320 million per in vivo target in development and commercial milestone payments plus mid-single-digit royalties on future sales. Lonvo-z is wholly owned. Additional revenue flows from licensing arrangements with AvenCell Therapeutics (ex vivo CAR-T programs) and Kyverna Therapeutics (allogeneic CD19 CAR-T for autoimmune disease). No genome editing in vivo therapy has been approved in the U.S., EU, or other key jurisdictions, and neither lonvo-z nor nex-z has received marketing authorization.
Show full overview
The company's near-term value depends on two binary clinical readouts. Lonvo-z's HAELO Phase 3 primary endpoint — HAE attacks from week 5 through week 28 — is due mid-2026; a missed endpoint would eliminate the planned H1 2027 commercial launch and BLA submission timeline. For nex-z, the MAGNITUDE Phase 3 trial for ATTR-CM remains on FDA clinical hold following a Grade 4 liver injury and patient death reported in October 2025; Intellia has stated it cannot predict when the MAGNITUDE trial may resume, and failure to resolve the hold could prevent commercialization of the ATTR-CM indication, the larger of the two ATTR patient populations.
See also: Healthcare · Biotechnology
From Intellia Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-27Recent Developments — Intellia Therapeutics, Inc.
Latest news
- NEWS This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday — benzinga Jul 16, 2026 neutral
- NEWS Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target — benzinga Jul 16, 2026 negative
- NEWS Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain — benzinga Jul 10, 2026 neutral
- NEWS Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17 — benzinga Jul 10, 2026 positive
- NEWS Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED) — benzinga Jun 29, 2026 positive
Generated 2026-07-27T14:48:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelonvo-z (HAE)10-K Item 1: 'Lonvo-z and nex-z are currently in Phase 3 clinical development, and we are preparing for the planned commercial launch of lonvo-z in the first half of 2027'
- HIGHpipelinenex-z (ATTR amyloidosis)10-K Item 1A: 'the FDA placed a clinical hold on the IND applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials ... a patient who was dosed with nex-z in the MAGNITUDE trial'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Revenue shrinking — -9.5% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 8.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 41%; Elevated put/call ratio: 2.85; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.39. Score 3.7/10, high confidence.
Take-profit target: $23.55 (+117.1% upside). Prior stop was $10.39. Stop-loss: $10.39.
Concentration risk — Pipeline: lonvo-z (HAE); Concentration risk — Pipeline: nex-z (ATTR amyloidosis); Quality below floor (1.8 < 4.0).
Intellia Therapeutics, Inc. trades at a P/E of N/A (forward -6.1). TrendMatrix value score: 5.4/10. Verdict: Sell.
27 analysts cover NTLA with a consensus score of 3.7/5. Average price target: $26.
What does Intellia Therapeutics, Inc. do?Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary...
Intellia Therapeutics is a pre-commercial CRISPR gene editing company with two Phase 3 programs: lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis, both designed as one-time in vivo treatments. The planned U.S. commercial launch for lonvo-z targets the first half of 2027; revenue currently comes from collaboration arrangements including a cost- and profit-sharing agreement with Regeneron for nex-z.